Skip to main content
Lab technician)

R&D Cardiovascular & Metabolic

Cardiovascular & Metabolic

The cardiovascular and metabolic therapeutic area is focused on improving and extending the lives of patients with cardiovascular disease (CVD) and diabetes.

Bern manufactoring employees with bottles

The largest clinical trial ever undertaken by CSL Behring is continuing with CSL112, a novel human plasma-derived apolipoprotein A-I, to reduce the risk of recurrent cardiovascular events during the 90-day high-risk period following a heart attack, the period when the majority of first year recurrent cardiovascular events occur. If successful, CSL112 will be the first therapy to demonstrate cardiovascular risk reduction through the novel apoA-I mechanism and will transform how acute myocardial infarction patients at high-risk of recurrent cardiovascular events are treated. 

Beyond CVD, type 2 diabetes is one of the fastest growing chronic diseases. Our innovative anti-VEGF-B monoclonal antibody therapy, CSL346, is being studied to augment the current standard of care to decrease the progression of diabetic kidney disease, a frequent long-term diabetic complication.

Cardiovascular disease is the leading cause of death globally, and the prevalence of diabetes is reaching almost epidemic proportions. Additional novel therapeutic opportunities are being explored and sought for the treatment of these serious diseases impacting global health.